Pfiz­er dumps a fad­ing pipeline star, giv­ing up on its PC­SK9 drug bo­co­cizum­ab

Paul M. Rid­ker, MD, SPIRE clin­i­cal tri­als pro­gram

You can scratch any hopes you might have had that Pfiz­er could mount a come-from-be­hind win and seize the lead from Am­gen and Sanofi/Re­gen­eron in the race of PC­SK9 cho­les­terol drugs. The phar­ma gi­ant has de­cid­ed to drop its can­di­date, bo­co­cizum­ab, cit­ing wan­ing ef­fi­ca­cy re­sults, a poor mar­ket re­cep­tion for the pi­o­neers, signs of an im­mune re­sponse to the drug and side ef­fects that would have like­ly marred its de­but.

Pfiz­er will now slam the brakes on two late-stage stud­ies — Spire-1 and Spire-2 — de­signed to test their drug in 32,000 pa­tients, a mas­sive­ly ex­pen­sive en­deav­or that went look­ing for the kinds of out­comes da­ta that could win over pay­ers. And it’s tak­ing a $0.04 R&D charge on the move.

Pfiz­er’s shares dropped 2.2% on the de­ci­sion in pre-mar­ket trad­ing Tues­day.

The move marks the ter­mi­na­tion of one of the phar­ma gi­ant’s biggest late-stage clin­i­cal ef­forts, leav­ing it still in the hunt for new drugs that can whip up some en­thu­si­asm from an­a­lysts.

Am­gen and Sanofi/Re­gen­eron sparked big hopes for their fran­chise plays in this field, bat­tling each oth­er for first-mover po­si­tion and vow­ing to jump out in front in the strug­gle to seize a mar­ket worth bil­lions. So far, though, the com­pa­nies have been bru­tal­ly dis­ap­point­ed by the ane­mic ini­tial de­mand for these ther­a­pies, as pay­ers kick back on the cost. That soft launch com­bined with ev­i­dence that Pfiz­er’s drug may not have mea­sured up well, ev­i­dent­ly played a key role in the de­ci­sion to kill it af­ter spend­ing hun­dreds of mil­lions of dol­lars on de­vel­op­ment.

Bar­clays dis­cussed it with Pfiz­er ex­ecs, and came away with this con­clu­sion:

Of note, the de­ci­sion to dis­con­tin­ue bo­co­cizum­ab was not in­flu­enced by any on­go­ing out­comes da­ta or feed­back from the da­ta mon­i­tor­ing com­mit­tee; the tri­als are still blind­ed. In our view, the cul­prit was the pres­ence of an­ti-drug an­ti­bod­ies (ADAs). Of note, from the pub­lished phase 2 da­ta from bo­co­cizum­ab, the ADA rate was ~7%.  It seemed to us that the pres­ence of ADAs in some pa­tients on bo­co­cizum­ab be­came prob­lem­at­ic, with a mi­nor­i­ty of pa­tients hav­ing a ‘sub­stan­tial lev­el’ of ADAs and a larg­er num­ber hav­ing a high­er back­ground lev­el. In our view, this like­ly wouldn’t have af­fect­ed the over­all prob­a­bil­i­ty of suc­cess in the SPIRE-1 or SPIRE-2, but it would present chal­lenges com­mer­cial­ly, where Am­gen’s Repatha or Re­gen­eron’s Pralu­ent haven’t seen an ADA rate in that range. And it does ex­plain an at­ten­u­a­tion of LDL-C ef­fect with bo­co­cizum­ab.

Pfiz­er had al­ready read out da­ta from the first 4 of 6 stud­ies in the late-stage pro­gram, reg­u­lar­ly tout­ing its ef­fi­ca­cy and pro­mot­ing its mar­ket­ing hopes in the field. Now The Med­i­cines Com­pa­ny, part­nered with Al­ny­lam, will move up to the third spot in this race with a PC­SK9 drug that a may on­ly need twice-year­ly dos­ing.

Pfiz­er has one of the weak­est late-stage pipelines in Big Phar­ma, and this set­back was not­ed by sev­er­al an­a­lysts, in­clud­ing Leerink’s Sea­mus Fer­nan­dez, who said: “This re­moves an im­por­tant Ph3 pipeline prod­uct for PFE while elim­i­nat­ing a ma­jor pot’l com­peti­tor for AMGN (MP) and SNY/REGN.”

Aside from the new­ly ac­quired PARP ta­la­zoparib, the check­point in­hibitor avelum­ab part­nered with Mer­ck KGaA and the SGLT2 di­a­betes drug er­tugliflozin part­nered with Mer­ck, Pfiz­er doesn’t have much that’s new in late-stage stud­ies. Much of its Phase III ef­fort is now giv­en to biosim­i­lars.

Pfiz­er promised to hus­tle out the da­ta on its de­funct PC­SK9 drug for fur­ther dis­cus­sion.

“To hon­or the al­tru­ism of tri­al par­tic­i­pants, and to max­i­mize the clin­i­cal and sci­en­tif­ic knowl­edge de­rived from the halt­ed tri­als, Pfiz­er has com­mit­ted to en­sur­ing that the da­ta will be made avail­able to study lead­ers for in­de­pen­dent analy­sis and prompt pub­lic pre­sen­ta­tion. We be­lieve the avail­able da­ta will al­low us to test the core sci­en­tif­ic ques­tions posed by the over­all pro­gram which is in the best in­ter­est of pa­tients who vol­un­teered in these clin­i­cal tri­als, and for pa­tients world­wide who suf­fer from heart dis­ease,” stat­ed Paul M. Rid­ker, MD, Co-chair Ex­ec­u­tive Com­mit­tee, SPIRE clin­i­cal tri­als pro­gram and di­rec­tor for Car­dio­vas­cu­lar Dis­ease Pre­ven­tion, Brigham and Women’s Hos­pi­tal.

Biogen CEO Michel Vounatsos (via Getty Images)

With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

With its FDA pitch on the Alzheimer’s drug aducanumab hanging perilously close to disaster, Biogen is rolling the dice on a $3.1 billion deal that brings in commercial rights to one of the other spotlight neuro drugs in late-stage development — after it already failed its first Phase III.

The big biotech has turned to Sage Therapeutics for its latest deal, close to a year after the crushing failure of Sage-217, now dubbed zuranolone, in the MOUNTAIN study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

In mid-August, as Kodak’s $765 million government-backed push into drug manufacturing slowly fell apart in national headlines, Ginkgo Bioworks CEO Jason Kelly got a message from his company’s government liaison: HHS wanted to know if they, too, might want a loan.

The government’s decision to lend Kodak three quarters of a billion dollars raised eyebrows because Kodak had never made drugs before. But Ginkgo, while not a manufacturing company, had spent the last decade refining new ways to produce materials inside cells and building automated facilities across Boston.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Bahija Jallal (file photo)

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

Bahija Jallal’s crew at TCR pioneer Immunocore says they have nailed down a promising set of pivotal data for their lead drug in a frontline setting for a solid tumor. And they are framing this early interim readout as the convincing snapshot they need to prove that their platform can deliver on a string of breakthrough therapies now in the clinic or planned for it.

In advance of the Monday announcement, Jallal and R&D chief David Berman took some time to walk me through the first round of Phase III data for their lead TCR designed to treat rare, frontline cases of metastatic uveal melanoma that come with a grim set of survival expectations.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vivek Ramaswamy (Jeff Rumans/JPM 2020)

Urovan­t's lead drug dis­ap­points in mid-stage study as first big FDA de­ci­sion looms

Just as Urovant gets ready for its first big FDA decision on vibegron, the drug has flopped in what would’ve been a follow-on indication.

In a Phase IIa trial involving women with abdominal pain due to irritable bowel syndrome, vibegron failed to meet the bar on improving “average worst abdominal pain” over 12 weeks, compared to placebo, among IBS-D patients.

There were actually slightly more responders in the placebo group than in the drug arm, with only 40.9% of those randomized to vigebron achieving at least a 30% decrease in “worst abdominal pain” in the past 24 hours. The trial enrolled 222 women but only 189 completed the study.

Gen­mab ax­es an ADC de­vel­op­ment pro­gram af­ter the da­ta fail to im­press

Genmab $GMAB has opted to ax one of its antibody-drug conjugates after watching it flop in the clinic.

The Danish biotech reported Tuesday that it decided to kill their program for enapotamab vedotin after the data gathered from expansion cohorts failed to measure up. According to the company:

While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers. Accordingly, the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.

Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

Vas Narasimhan's 'Wild Card' drugs: No­var­tis CEO high­lights po­ten­tial jack­pots, as well as late-stage stars, in R&D pre­sen­ta­tion

Novartis is always one of the industry’s biggest R&D spenders. As they often do toward the end of each year, company execs are highlighting the drugs they expect will most likely be winners in 2021.

And they’re also dreaming about some potential big-time lottery tickets.

As part of its annual investor presentation Tuesday, where the company allows investors and analysts to virtually schmooze with the bigwigs, Novartis CEO Vas Narasimhan will outline what he thinks are the pharma’s “Wild Cards.” The slate of five experimental drugs are those that Novartis hopes can be high-risk, high-reward entrants into the market over the next half-decade or so, and cover a wide range of indications.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.